Author:
Leblanc Dominique,Cantin Guy,Desnoyers Alexandra,Dufresne Jean,Masucci Giuseppina Laura,Panet-Raymond Valérie,Poirier Éric,Soldera Sara,Gingras Isabelle
Abstract
Patients with oligometastatic breast cancer (BC) are candidates of choice for metastasis-directed therapy (MDT). This paper summarizes the opinions of an expert committee about the management of oligometastatic BC. The experts could complete the questionnaire from 13 September 2021, to 10 October 2021, followed by a discussion. The experts were physicians working in the Province of Quebec (Canada) and specialized in BC care, including surgical oncologists, medical oncologists, and radiation oncologists. The experts provided their opinions about the context of the disease and therapeutic approach, local and systemic therapies, and the prognosis of oligometastatic BC. In addition to the expert panel’s opinions about the management of oligometastatic disease per se, the experts stated that a prospective data registry should be implemented to collect data about oligometastatic BC to improve knowledge about oligometastatic BC and implement data-driven MDT. These data could also allow for the design of treatment algorithms. In conclusion, this paper presents the expert panel’s opinions about the management of oligometastatic BC and highlights the needs to be met to improve the care of this condition.
Reference72 articles.
1. Laboratory and clinical research in breast cancer—A personal adventure: The David A. Karnofsky memorial lecture;Fisher;Cancer Res.,1980
2. Historical perspective: Two decades of progress in treating metastatic colorectal cancer;Lee;J. Surg. Oncol.,2019
3. Historical background;Park;Prog Neurol Surg.,2012
4. Karnofsky Memorial Lecture. Natural history of small breast cancers;Hellman;J. Clin. Oncol.,1994
5. Oligometastases;Hellman;J. Clin. Oncol.,1995
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献